Your browser doesn't support javascript.
loading
The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Heikamp, Emily B; Henrich, Jill A; Perner, Florian; Wong, Eric M; Hatton, Charles; Wen, Yanhe; Barwe, Sonali P; Gopalakrishnapillai, Anilkumar; Xu, Haiming; Uckelmann, Hannah J; Takao, Sumiko; Kazansky, Yaniv; Pikman, Yana; McGeehan, Gerard M; Kolb, Edward A; Kentsis, Alex; Armstrong, Scott A.
Affiliation
  • Heikamp EB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Henrich JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Perner F; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Wong EM; Internal Medicine C, Greifswald University Medical Center, Greifswald, Germany.
  • Hatton C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Wen Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Barwe SP; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Gopalakrishnapillai A; Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE.
  • Xu H; Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE.
  • Uckelmann HJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Takao S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Kazansky Y; Tow Center for Developmental Oncology, Sloan Kettering Institute, and Department of Pediatrics, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center, New York, NY; and.
  • Pikman Y; Tow Center for Developmental Oncology, Sloan Kettering Institute, and Department of Pediatrics, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center, New York, NY; and.
  • McGeehan GM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Kolb EA; Syndax Pharmaceuticals, Inc., Waltham, MA.
  • Kentsis A; Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE.
  • Armstrong SA; Tow Center for Developmental Oncology, Sloan Kettering Institute, and Department of Pediatrics, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center, New York, NY; and.
Blood ; 139(6): 894-906, 2022 02 10.
Article in En | MEDLINE | ID: mdl-34582559

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Histone-Lysine N-Methyltransferase / Proto-Oncogene Proteins / Nuclear Pore Complex Proteins / Myeloid-Lymphoid Leukemia Protein Type of study: Prognostic_studies Limits: Animals Language: En Journal: Blood Year: 2022 Type: Article Affiliation country: Morocco

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Histone-Lysine N-Methyltransferase / Proto-Oncogene Proteins / Nuclear Pore Complex Proteins / Myeloid-Lymphoid Leukemia Protein Type of study: Prognostic_studies Limits: Animals Language: En Journal: Blood Year: 2022 Type: Article Affiliation country: Morocco